This article has been updated from a previous version to include information about the current status of Fluidigm's collaboration with Novartis.
Trovagene, a San Diego-based company that has spent several years attempting to commercialize molecular diagnostic tests based on detecting cell-free nucleic acids in urine, may have finally found its ideal detection technology: digital PCR.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.